Results 181 to 190 of about 8,252,790 (324)

Trends, lag and characteristics of rare disease drug approval in the USA and China, 1983-2022. [PDF]

open access: yesOrphanet J Rare Dis
Wang S   +11 more
europepmc   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

open access: yesMolecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis   +20 more
wiley   +1 more source

‘Civil society involvement in drug policy’ webinar.

open access: yes, 2018
On 30th November 2018, Ana Liffey Drug Project hosted a webinar about Civil Society Involvement in Drug Policy. The event included interviews with: Anna Quigley (CityWide) Tony Duffin (Ana Liffey Drug Project) Aoife Frances (National Family Support ...

core  

Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot. [PDF]

open access: yesCurr Probl Cancer, 2023
Matthew-Onabanjo AN   +10 more
europepmc   +1 more source

Versatile vector tools for efficient protein screening across multiple expression systems

open access: yesFEBS Open Bio, EarlyView.
A unified vector toolkit enables rapid protein expression screening across E. coli, insect, and mammalian cells. A single primer pair amplifies the target gene, which is inserted into any vector via a standardized interface. This streamlined workflow eliminates repeated cloning steps, accelerating the identification of optimal expression conditions for
Zhimin Zhu   +5 more
wiley   +1 more source

Training toolkit on drug policy advocacy.

open access: yes, 2013
This training toolkit has been developed by the International Drug Policy Consortium (IDPC) and the Eurasian Harm Reduction Network (EHRN) to build the capacity of civil society organisations for engaging with, and influencing, drug policy making ...

core  

Home - About - Disclaimer - Privacy